The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
37121562
DOI
10.1016/j.clinbiochem.2023.04.011
PII: S0009-9120(23)00083-8
Knihovny.cz E-resources
- Keywords
- DLX1, Diagnostics, HOXC6, PCA3, Prostate cancer, RNA, TMPRSS2:ERG, Urinary marker,
- MeSH
- Antigens, Neoplasm * genetics MeSH
- Oncogene Proteins, Fusion genetics urine MeSH
- Homeodomain Proteins genetics MeSH
- Humans MeSH
- Biomarkers, Tumor urine MeSH
- Prostatic Neoplasms * diagnosis genetics MeSH
- Prostate pathology MeSH
- Prostate-Specific Antigen MeSH
- Retrospective Studies MeSH
- Serine Endopeptidases genetics MeSH
- Transcriptional Regulator ERG MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Antigens, Neoplasm * MeSH
- ERG protein, human MeSH Browser
- Oncogene Proteins, Fusion MeSH
- Homeodomain Proteins MeSH
- HOXC6 protein, human MeSH Browser
- Biomarkers, Tumor MeSH
- Prostate-Specific Antigen MeSH
- Serine Endopeptidases MeSH
- TMPRSS2 protein, human MeSH Browser
- Transcriptional Regulator ERG MeSH
BACKGROUND: Prostate cancer (PCa) is the second most commonly diagnosed cancer in men. To date, the role of the combined application of long non-coding RNAs (PCA3, DLX1, HOXC6, TMPRSS2:ERG) for obtaining the most accurate method of detection of PCa has not yet been comprehensively investigated. METHODS: In total 240 persons were included in the retrospective study. Among them were 150 patients with confirmed PCa, 30 patients with benign prostatic hyperplasia, 30 patients with active chronic prostatitis and 30 healthy volunteers. In all patients, the urine samples were collected prior to biopsy or treatment. Polymerase chain reaction with reverse transcription was performed to detect the expression level of PCA3, HOXC6, DLX1 and the presence of the TMPRSS2:ERG transcript. RESULTS: PCA3 was detected in urine samples in all cases. Using a PCA3 score of 56 allowed the differentiation between PCa and all other cases with a sensitivity of 61% and specificity of 96% (p < 0.001) while a PCA3 score threshold value of 50 resulted in a differentiation between clinically significant PCa (ISUP grades 2-5) and all other cases with a sensitivity of 93% and specificity of 93% (p < 0.001). The TMPRSS2:ERG expression in urine was detected exclusively in the group of patients with PCa and only in 16% of all cases. CONCLUSIONS: PCA3 score detected in urine demonstrated moderate sensitivity and good specificity in differentiation between PCa and non-PCa and high sensitivity and specificity in differentiation between clinically significant PCa and non-PCa.
Department of Urology Danylo Halytsky Lviv National Medical University Ukraine
Department of Urology Regional Specialist Hospital Wroclaw Poland
Faculty of Health Sciences University of Ss Cyril and Methodius in Trnava Trnava Slovakia
References provided by Crossref.org